96 31 27 26 9 5 2 1 p.0.: 7.5-300 mg/sq.m. i.m.: 2.5-40 mg/sq.m. i.v.: 2.5-33600 mg/sq.m. i.th.: 6.25-15 mg/sq.m. Duration of MTX administration i.v.:l-5 min-48 h p.0.: 1 day-5 days i.m.:l day-7 days Starting dose of FA rescue 3-200 mg/sq.m.words MTX and children. The table illustrates the heterogeneity of the use of MTWfolinic acid rescue treatment in pediatric patients.Questions related to the clinical and cellular pharmacology of MTX lead to the basic problems of clinical oncology, tumor biology, biochemistry pharmacology, and genetics. However, they highlight the fact that MTX-related subjects may serve as a model in clinical and experimental cancer research. Although chemotherapeutic protocols containing methotrexate still include many features based on empiricism rather than pharmacokinetic findings, it is also true that the practical application of the results of clinical pharmacologic studies has been the most extensive and advanced for the case of methotrexate, compared with other cytostatics.
CLINICAL PHARMACOKINETICS OF METHOTREXATEThe absorption of M T X after oral administration has been reported to be between 47% and 83% of the dose.'" The absolute mean bioavailability of the drug was found to be 33% (range 13%-76%) in a study from the St. Jude Children's Research H~s p i t a l .~ At dosages higher than 40 mg/m2 the bioavailability of the drug was significantly lower (17.5%; range 12.7%-22.3%) in the same study. Food is affecting the absorption of M T X (e.g., milky meal)4 and decreases the absorption of the drug. Remarkable interindividual variations are expressed in the rate and the extent of the absorption of MTX. It has been suggested that patients could be divided into fast and slow absorbers, based on M T X serum levels 1 hour after adrninistrati~n.~ This appears to be clinically important as slow absorbers seem to have a higher relapse rate of Pediatr Hematol Oncol Downloaded from informahealthcare.com by UB Giessen on 12/14/14For personal use only.